In a patient with atrioventricular reentrant tachycardia who declines catheter ablation, which β‑blocker—propranolol or bisoprolol—is preferred for chronic medical therapy?

β‑Blocker Selection for Chronic AVRT Management

For a patient with AVRT who declines catheter ablation, either propranolol or bisoprolol is acceptable, as guidelines recommend β‑blockers as a class without specifying individual agents—however, β₁‑selective agents like bisoprolol are generally preferred in clinical practice for their better tolerability and reduced risk of bronchospasm.

Guideline Framework

The 2020 ESC guidelines upgraded the strength of recommendation for β‑blockers in both acute and chronic management of AVRT 1. The 2015 ACC/AHA/HRS guidelines provide a Class I recommendation for oral β‑blockers in ongoing management of AVNRT (a closely related reentrant tachycardia), though the evidence base is limited 2. The single study cited used propranolol 240 mg/day and demonstrated similar efficacy to verapamil and digoxin 2.

Critical point: Guidelines do not distinguish between specific β‑blockers for AVRT prophylaxis. The evidence supporting β‑blockers comes primarily from older studies using propranolol, but this reflects historical prescribing patterns rather than superior efficacy.

Pharmacologic Considerations

Propranolol Characteristics

• Non-selective β‑blocker (blocks both β₁ and β₂ receptors) 3
• Lipophilic with high CNS penetration
• Extensive first-pass metabolism (~20%) 3
• Demonstrated efficacy in AVRT: prolongs retrograde AV nodal conduction and increases ventriculoatrial block cycle length 4
• Combined propranolol + digoxin showed effectiveness in 7 of 22 patients with AVRT 5

Bisoprolol Characteristics

• β₁‑selective (cardioselective) at therapeutic doses 6
• Selectivity maintained at doses ≤20 mg; higher doses lose selectivity 6
• 80% bioavailability, minimal first-pass metabolism 6
• 9-12 hour half-life allowing once-daily dosing 6
• Proven efficacy in supraventricular arrhythmias including rate control 7
• In a randomized trial for AVNRT, bisoprolol 5 mg daily was used (though combined with diltiazem in some patients) 8

Clinical Decision Algorithm

Choose bisoprolol if:

• Patient has asthma, COPD, or reactive airway disease (β₁‑selectivity reduces bronchospasm risk)
• Once-daily dosing preferred for adherence
• Patient has diabetes (less masking of hypoglycemia symptoms compared to non-selective agents)
• Elderly patient (predictable pharmacokinetics, renal/hepatic adjustment straightforward) 6

Choose propranolol if:

• Historical precedent matters (more published data specifically for AVRT)
• Patient requires multiple daily dosing anyway
• Cost is a major factor (generic propranolol typically less expensive)
• Patient has concurrent migraine prophylaxis indication

Avoid both if:

• Severe bradycardia or high-degree AV block
• Decompensated heart failure
• Severe peripheral vascular disease
• Pre-excited atrial fibrillation (β‑blockers contraindicated) 1

Practical Prescribing

Starting Doses

• Bisoprolol: 2.5-5 mg once daily, titrate to 10 mg if needed 8
• Propranolol: 40-80 mg twice daily, titrate to 240 mg/day in divided doses 2

Monitoring

• Baseline ECG and heart rate
• Recheck heart rate and symptoms at 1-2 weeks
• Titrate based on symptom control and tolerability
• Watch for excessive bradycardia (<50 bpm), fatigue, or hypotension

Important Caveats

The elephant in the room: Catheter ablation has >95% success rates with <1% risk of AV block 2. Medical therapy is inherently second-line. The 2019 ESC guidelines explicitly state ablation should be offered as initial choice (Class I) 1. A 2017 randomized trial showed that 25% of patients on AAD therapy (bisoprolol/diltiazem) discontinued within 3 months, and 68% required hospital admission for cardioversion over 5 years versus 0% in the ablation group 8.

If the patient refuses ablation: Document the discussion thoroughly. Educate on vagal maneuvers and consider "pill-in-the-pocket" approach for breakthrough episodes. Arrange cardiology follow-up to reassess ablation candidacy, as many patients change their minds after experiencing medication side effects or breakthrough arrhythmias.

Pregnancy consideration: If patient is a woman of childbearing age, note that β₁‑selective blockers (not atenolol) are preferred during pregnancy, though flecainide/propafenone are first-line for WPW 1. Propranolol is specifically no longer recommended during pregnancy 1.